US · SLN · BIOTECHNOLOGY
Silence Therapeutics plc (SLN) intrinsic value and stock valuation
$19.81as of 2026-11-21 · Mkt cap 564.45M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Silence Therapeutics plc DCF and intrinsic value
InvestorsCraft values SLN with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from SLN’s statements →
Silence Therapeutics plc Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2011–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Alto Neuroscience, Inc. (ANRO) $25.37
- Contineum Therapeutics, Inc. (CTNM) $8.68
- Kyverna Therapeutics, Inc. (KYTX) $4.26
- Lexeo Therapeutics, Inc. Common Stock (LXEO) $2.96
- Lyell Immunopharma, Inc. (LYEL) $13.80
- Amarin Corporation plc (AMRN) $10.57
- AC Immune S.A. (ACIU) $1.95
- Capricor Therapeutics, Inc. (CAPR) $7.59
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $560K | $43.3M | $25.4M | $17.7M | $12.4M |
| Operating income | -$-89.75M | -$-63.32M | -$-49.6M | -$-49.76M | -$-45.81M |
| Net income | -$-88.61M | -$-45.31M | -$-43.27M | -$-41.03M | -$-39.41M |
| EPSd | -$-1.88M | -$-2.94M | -$-3.5M | -$-3.82M | -$-1.33M |
| Operating cash flow | -$-62.27M | -$-54.05M | -$-39.35M | -$-57.04M | $9.19M |
| Capital expenditure | -$-60K | -$-170K | -$-40K | -$-550K | -$-1.8M |
| Free cash flow | -$-62.33M | -$-54.22M | -$-39.4M | -$-57.59M | $7.39M |
| Total assets | $131.4M | $161.9M | $119.5M | $107.5M | $96.2M |
| Total debt | $160K | $90K | $350K | $450K | $140K |
| Net debt | -$-11.12M | -$-96.86M | -$-68.44M | -$-54.37M | -$-73.4M |
| Total equity | $62.3M | $107.1M | $22M | $22.1M | $8.53M |
| Cash and short-term investments | $85.1M | $117.7M | $68.8M | $71.1M | $73.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $560K | $43.3M | $25.4M | $17.7M | $12.4M |
| Cost of revenue | $210K | $11.8M | $10.3M | $11M | $7.46M |
| Gross profit | $340K | $31.5M | $15.1M | $6.68M | $4.96M |
| Research and development expenses | $67.8M | $67.9M | $44M | $35.5M | $30.8M |
| Selling, general and administrative expenses | $22.3M | $26.9M | $20.6M | $20.9M | $20M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $90.1M | $94.8M | $64.7M | $56.4M | $50.8M |
| Cost and expenses | $90.3M | $106.6M | $75M | $67.4M | $58.2M |
| Interest income | $3.48M | $4.47M | $1.45M | $230K | $10K |
| Interest expense | $0.00 | $0.00 | $30K | $50K | $10K |
| Depreciation and amortization | $560K | $590K | $500K | $490K | $430K |
| Ebitda | -$-88.05M | -$-48.99M | -$-49.78M | -$-39.94M | -$-45.42M |
| Operating income | -$-89.75M | -$-63.32M | -$-49.6M | -$-49.76M | -$-45.81M |
| Total other income/expenses, net | $1.15M | $18.9M | -$-710K | $9.29M | -$-40K |
| Income before tax | -$-88.6M | -$-44.46M | -$-50.31M | -$-40.47M | -$-45.86M |
| Income tax expense | $10K | $840K | -$-7.04M | $560K | -$-6.45M |
| Net income | -$-88.61M | -$-45.31M | -$-43.27M | -$-41.03M | -$-39.41M |
| Weighted average shares outstanding | $47.2M | $15.4M | $12.4M | $10.7M | $29.7M |
| Weighted average diluted shares outstanding | $47.2M | $15.4M | $12.4M | $10.7M | $29.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $85.1M | $117.7M | $68.8M | $71.1M | $73.5M |
| Net receivables | $24.6M | $21.5M | $24M | $920K | $330K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $118.7M | $149.7M | $103.2M | $96.7M | $86.3M |
| Property, plant and equipment, net | $1.75M | $1.58M | $2.31M | $2.2M | $1.94M |
| Goodwill and intangible assets | $10.9M | $7.75M | $10.3M | $8.33M | $7.62M |
| Long-term investments | $0.00 | $0.00 | $0.00 | $280K | $300K |
| Total non-current assets | $12.8M | $12.2M | $16.3M | $10.8M | $9.86M |
| Total assets | $131.4M | $161.9M | $119.5M | $107.5M | $96.2M |
| Accounts payable | $4.41M | $2.95M | $3.35M | $3.19M | $4.07M |
| Short-term debt | $90K | $90K | $460K | $450K | $140K |
| Deferred revenue | $170K | $240K | $6.57M | $0.00 | $0.00 |
| Total current liabilities | $13.6M | $13.4M | $22.3M | $21.9M | $15.2M |
| Long-term debt | $70K | $0.00 | $120K | $0.00 | $0.00 |
| Deferred revenue, non-current | $55.5M | $41.4M | $75M | $0.00 | $0.00 |
| Total non-current liabilities | $55.5M | $41.4M | $75.1M | $63.5M | $72.5M |
| Capital lease obligations | $160K | $90K | $350K | $450K | $140K |
| Total liabilities | $69.1M | $54.8M | $97.5M | $85.4M | $87.7M |
| Common stock | $10.3M | $8.22M | $8.85M | $5.39M | $4.49M |
| Retained earnings | -$-562.57M | -$-378.8M | -$-431.89M | -$-263.26M | -$-222.97M |
| Accumulated other comprehensive income (loss) | -$-2.98M | -$-9.41M | $40.4M | $53.3M | $42.7M |
| Total equity | $62.3M | $107.1M | $22M | $22.1M | $8.53M |
| Total investments | $73.8M | $20.8M | $0.00 | $16.6M | $300K |
| Total debt | $160K | $90K | $350K | $450K | $140K |
| Net debt | -$-11.12M | -$-96.86M | -$-68.44M | -$-54.37M | -$-73.4M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-88.61M | -$-28.92M | -$-50.31M | -$-50.33M | -$-61.89M |
| Depreciation and amortization | $560K | $470K | $500K | $600K | $580K |
| Stock-based compensation | $8.07M | $10.4M | $13.1M | $12.7M | $11.7M |
| Change in working capital | $10.2M | -$-26.39M | -$-11.66M | -$-19.4M | $52.4M |
| Accounts receivable | $5.07M | -$-720K | $310K | -$-10.54M | $37.1M |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash provided by operating activities | -$-62.27M | -$-54.05M | -$-39.35M | -$-57.04M | $9.19M |
| Investments in property, plant and equipment | -$-60K | -$-170K | -$-40K | -$-170K | -$-1.77M |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for investing activities | -$-47.99M | -$-17.55M | $16.4M | -$-20.5M | $11.7M |
| Common stock issued | $10K | $113.5M | $25.3M | $52.6M | $41.7M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | $10K | $113.5M | $25.2M | $52.6M | $41.5M |
| Net change in cash | -$-110.05M | $42M | -$-790K | -$-33.08M | $62.2M |
| Cash at end of period | $11.3M | $97M | $54M | $66.3M | $99.3M |
| Operating cash flow | -$-62.27M | -$-54.05M | -$-39.35M | -$-57.04M | $9.19M |
| Capital expenditure | -$-60K | -$-170K | -$-40K | -$-550K | -$-1.8M |
| Free cash flow | -$-62.33M | -$-54.22M | -$-39.4M | -$-57.59M | $7.39M |
Line items
Line items
Line items
About Silence Therapeutics plc
Silence Therapeutics plc is a London, UK-based biotechnology company specializing in the research and development of groundbreaking ribonucleic acid (RNA) therapeutics. Its therapeutic focus areas include hematological, cardiovascular, and various rare and metabolic conditions. Central to their innovative approach is the mRNAi GalNAc Oligonucleotide Discovery platform, which is designed for precise targeting of specific disease-causing genes within the liver. The company's methodology harnesses the body's natural RNA interference (RNAi) mechanism by designing short interfering RNA (siRNA) molecules that degrade messenger RNA (mRNA), thereby preventing the production of targeted disease-associated proteins. Their pipeline features several promising candidates, including SLN360, currently in Phase I clinical trials for cardiovascular disease associated with elevated lipoprotein. Another key candidate, SLN124, is undergoing Phase I clinical trials for non-transfusion-dependent thalassemia and myelodysplastic syndrome, with further development planned for polycythemia vera. Silence Therapeutics also engages in strategic collaborations to expand its reach. It has agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for cardiovascular, renal, metabolic, and respiratory diseases. Furthermore, a partnership with Mallinckrodt Pharma IP Trading DAC aims to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company is also collaborating with Hansoh Pharmaceutical Group Company Limited to develop siRNAs for three unspecified targets, utilizing Silence's mRNAi GOLD platform. Originally incorporated as SR Pharma plc, the company rebranded to Silence Therapeutics plc in May 2007.
- CEO
- Iain Gladstone Ross
- Employees
- 88
- Beta
- 1.34
Explore
Frequently asked questions
What is the intrinsic value of Silence Therapeutics plc (SLN)?
Silence Therapeutics plc (SLN) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is SLN undervalued?
SLN trades at a price of $19.81 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.